Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and β-cell dysfunction
AssigneeMeck Patent GmbH
InventorsNorbert Beier, Wolfgang Scholz, Ulrich Betz, Marian Braendle
Life of this patent
Estimating the term…
Abstract
The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of Type II diabetes mellitus, the Metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of ß-cell compensation.
Claims13
A method for the treatment of the arising symptoms of a disease that is associated with ß-cell dysfunction having reduced ß-cell compensation, comprising administering to a patient who has not progressed to type II diabetes an effective amount of an active ingredient which is 2-methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, and/or a physiologically acceptable salt and/or solvate thereof, such that the ß-cell dysfunction in the patient is decreased, wherein the 2-methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine and/or a physiologically acceptable salt and/or solvate thereof acts as direct insulin secretagogue and wherein the pancreatic ß-cell compensation in the patient is preserved to at least 70% of baseline prior to usage.
A method for the treatment of ß-cell dysfunction having reduced ß-cell compensation in a patient who has not progressed to type II diabetes, comprising administering to the patient an effective amount of an active ingredient which is 2-methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, and/or a physiologically acceptable salt and/or solvate thereof, wherein the 2-methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine and/or a physiologically acceptable salt and/or solvate thereof acts as direct insulin secretagogue and wherein the pancreatic ß-cell compensation in the patient is preserved to at least 70% of baseline prior to usage.
Dependencies are inferred from the claim text.